ArticleCureus2025
Advanced Stage IVb Classical Hodgkin's Lymphoma in a 9/11 First Responder: The Persistent Health Risks and Impact of Environmental Exposures.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report details the clinical journey of a first responder from the events of 9/11 who presented with significant B symptoms and right hip pain, ultimately diagnosed with stage IVb classical Hodgkin's lymphoma with extensive metastasis. Imaging revealed a right proximal femoral mass, mediastinal and supraclavicular nodal metastases, and multiple hypermetabolic splenic masses, emphasizing the aggressive nature of the disease and the importance of early detection and prompt management. Following referral to an oncologist, the patient was treated with six cycles of the chemotherapy regimen consisting of brentuximab plus doxorubicin, vinblastine, and decarbazine (brentuximab-AVD) without the need for surgical excision. A follow-up PET/CT scan seven months after diagnosis showed no active tumors, indicating that the patient was in remission. Three years following the initial diagnosis, the patient displays no signs of recurrence and continues to remain B-symptom-free. He does report lingering intermittent and stable right hip pain managed with medications as needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.